department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Adakveo · pharmadog

pharmadog
drugs
Adakveo

drug

patient view →

crizanlizumab

Marketedupdated 2mo ago

by $NVS NOVARTIS AG

Approved

community read0 votes

indications

investigational

Sickle Cell Disease

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Adakveo

generic

crizanlizumab-tmca

indication

Sickle Cell Disease

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 21m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Trials studying crizanlizumab

phase3Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patientsactive not recruitingn=255
—Managed Access Programs for SEG101, Crizanlizumabavailable
phase4Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Studyrecruitingn=130
phase3A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)recruitingn=315
phase2A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapismcompletedn=36
phase2Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patientscompletedn=117
phase4An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patientscompletedn=140
phase2Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patientsterminatedn=45

more trials →